The FOXO family of transcription factors: key molecular players in gastric cancer

Liu, Ying; Ao, Xiang; Jia, Yi; Li, Xiaoge; Wang, Yu; Wang, Jianxun

doi:10.1007/s00109-022-02219-x

Cited by 26 publications

(13 citation statements)

References 169 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cancer immune evasion has emerged as a major hurdle for successful anticancer therapies (144)(145)(146). Cancer cells exploit multiple immunological processes including enhancement of immunosuppressive cell function, interference with antigen presentation, upregulation of immunosuppressive mediators, induction of immune tolerance and lymphocyte apoptosis.…”

Section: Tumor Immunitymentioning

confidence: 99%

The crosstalk between the gut microbiota and tumor immunity: Implications for cancer progression and treatment outcomes

et al. 2023

View full text Add to dashboard Cite

The gastrointestinal tract is inhabited by trillions of commensal microorganisms that constitute the gut microbiota. As a main metabolic organ, the gut microbiota has co-evolved in a symbiotic relationship with its host, contributing to physiological homeostasis. Recent advances have provided mechanistic insights into the dual role of the gut microbiota in cancer pathogenesis. Particularly, compelling evidence indicates that the gut microbiota exerts regulatory effects on the host immune system to fight against cancer development. Some microbiota-derived metabolites have been suggested as potential activators of antitumor immunity. On the contrary, the disequilibrium of intestinal microbial communities, a condition termed dysbiosis, can induce cancer development. The altered gut microbiota reprograms the hostile tumor microenvironment (TME), thus allowing cancer cells to avoid immunosurvelliance. Furthermore, the gut microbiota has been associated with the effects and complications of cancer therapy given its prominent immunoregulatory properties. Therapeutic measures that aim to manipulate the interplay between the gut microbiota and tumor immunity may bring new breakthroughs in cancer treatment. Herein, we provide a comprehensive update on the evidence for the implication of the gut microbiota in immune-oncology and discuss the fundamental mechanisms underlying the influence of intestinal microbial communities on systemic cancer therapy, in order to provide important clues toward improving treatment outcomes in cancer patients.

show abstract

Section: Tumor Immunitymentioning

confidence: 99%

The crosstalk between the gut microbiota and tumor immunity: Implications for cancer progression and treatment outcomes

et al. 2023

View full text Add to dashboard Cite

show abstract

“…For instance, ncRNAs are classified into housekeeping ncRNAs (e.g., rRNAs and tRNAs) and regulatory ncRNAs (e.g., miRNAs, circRNAs and lncRNAs) based on their cellular functions. According to their transcript size, ncRNAs are divided into lncRNAs (> 200 nucleotides) and small ncRNAs (< 200 nucleotides), including miRNAs, small interfering RNAs (siRNAs), and piwi-interacting RNAs (piRNAs) ( 22 , 23 ). Besides, lncRNAs are sorted into two categories, linear lncRNAs and circular lncRNAs based on their structure ( 24 ).…”

Section: Overview Of Ncrnasmentioning

confidence: 99%

Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications

Zhou

Jia

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Cancer is one of the most frequently diagnosed malignant diseases worldwide, posing a serious, long-term threat to patients’ health and life. Systemic chemotherapy remains the first-line therapeutic approach for recurrent or metastatic cancer patients after surgery, with the potential to effectively extend patient survival. However, the development of drug resistance seriously limits the clinical efficiency of chemotherapy and ultimately results in treatment failure and patient death. A large number of studies have shown that non-coding RNAs (ncRNAs), particularly microRNAs, long non-coding RNAs, and circular RNAs, are widely involved in the regulation of cancer drug resistance. Their dysregulation contributes to the development of cancer drug resistance by modulating the expression of specific target genes involved in cellular apoptosis, autophagy, drug efflux, epithelial-to-mesenchymal transition (EMT), and cancer stem cells (CSCs). Moreover, some ncRNAs also possess great potential as efficient, specific biomarkers in diagnosis and prognosis as well as therapeutic targets in cancer patients. In this review, we summarize the recent findings on the emerging role and underlying mechanisms of ncRNAs involved in cancer drug resistance and focus on their clinical applications as biomarkers and therapeutic targets in cancer treatment. This information will be of great benefit to early diagnosis and prognostic assessments of cancer as well as the development of ncRNA-based therapeutic strategies for cancer patients.

show abstract

“…PTMs are dynamic and reversible processes occurring in protein during or after their synthesis. They play a vital role in modulating protein functions such as subcellular localization, stability, and activity Liu et al 2022c ; Liu et al 2022 h ). Studies have increasingly demonstrated that FADD can be modified by various PTMs, such as phosphorylation, ubiquitination, SUMOylation, and GlcNAcylation.…”

Section: Structure and Functions Of Faddmentioning

confidence: 99%

“…Biomarkers are considered a promising tool in the early diagnosis, prognostic assessment, and treatment of cancer patients (Ao et al 2020 ; Lu et al 2021 ). Some classical biomarkers (e.g., CEA, AFP, and CA72-4) have been clinically applied, but their unideal specificity and sensitivity restrict their further utilization (Liu et al 2022c ). Therefore, there is an urgent need in cancer treatment for the exploration of reliable biomarkers with high specificity and sensitivity.…”

Section: Clinical Applications Of Fadd In Cancer Treatmentmentioning

confidence: 99%

FADD as a key molecular player in cancer progression

Liu

Zhou

et al. 2022

Mol Med

Self Cite

View full text Add to dashboard Cite

Cancer is a leading disease-related cause of death worldwide. Despite advances in therapeutic interventions, cancer remains a major global public health problem. Cancer pathogenesis is extremely intricate and largely unknown. Fas-associated protein with death domain (FADD) was initially identified as an adaptor protein for death receptor-mediated extrinsic apoptosis. Recent evidence suggests that FADD plays a vital role in non-apoptotic cellular processes, such as proliferation, autophagy, and necroptosis. FADD expression and activity of are modulated by a complicated network of processes, such as DNA methylation, non-coding RNA, and post-translational modification. FADD dysregulation has been shown to be closely associated with the pathogenesis of numerous types of cancer. However, the detailed mechanisms of FADD dysregulation involved in cancer progression are still not fully understood. This review mainly summarizes recent findings on the structure, functions, and regulatory mechanisms of FADD and focuses on its role in cancer progression. The clinical implications of FADD as a biomarker and therapeutic target for cancer patients are also discussed. The information reviewed herein may expand researchers’ understanding of FADD and contribute to the development of FADD-based therapeutic strategies for cancer patients.

show abstract

The FOXO family of transcription factors: key molecular players in gastric cancer

Cited by 26 publications

References 169 publications

The crosstalk between the gut microbiota and tumor immunity: Implications for cancer progression and treatment outcomes

The crosstalk between the gut microbiota and tumor immunity: Implications for cancer progression and treatment outcomes

Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications

FADD as a key molecular player in cancer progression

Contact Info

Product

Resources

About